Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;12(10):11097-11106.
doi: 10.1002/cam4.5659. Epub 2023 Mar 7.

Advances in immune checkpoint inhibitors therapy for small cell lung cancer

Longhui Li  1   2 , Yangyueying Liang  1   2 , Minghui Yu  1   2 , Lu Zhao  1   2 , Qingyun Mei  1   2 , Yongchao Yu  1   2 , Na Wang  1   2 , Dou Zhang  1   2 , Ziwei Wang  1   2 , Yingjie Jia  1   2 , Fanming Kong  1   2
Affiliations
Review

Advances in immune checkpoint inhibitors therapy for small cell lung cancer

Longhui Li et al. Cancer Med. 2023 May.

Abstract

Background: As one of the most aggressive neuroendocrine tumors, small cell lung cancer (SCLC) has the most disappointing prognosis of all lung cancers. Although SCLC responds well to initial chemotherapy, the majority of patients experience disease recurrence within one year, and patient survival is poor. It is still necessary to explore the application of ICIs in SCLC since the beginning of the road to immunotherapy, which broke the 30-year treatment deadlock of SCLC.

Methods: We searched PubMed, Web of Science, and Embase with search terms such as "SCLC", "ES-SCLC", "ICIs", and "ICBs", and categorized and summarized the relevant literature obtained, and we compiled the latest progress about the application of ICIs in SCLC.

Results: We listed 14 clinical trials on ICIs, including 8 clinical trials on first-line SCLC treatment, 2 clinical trials on second-line SCLC treatment, 3 clinical trials on third-line SCLC treatment, and 1 clinical trial on SCLC maintenance treatment.

Conclusion: ICIs in combination with chemotherapy can improve OS in SCLC patients, but the extent to which SCLC patients can benefit from ICIs is limited, and ICIs' combination treatment strategies still need to be continuously explored.

Keywords: SCLC; clinical trials; immune checkpoint inhibitors; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

This article contains no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1‐9. doi:10.1016/j.jncc.2022.02.002 - DOI - PMC - PubMed
    1. Ortega‐Franco A, Ackermann C, Paz‐Ares L, Califano R. First‐line immune checkpoint inhibitors for extensive stage small‐cell lung cancer: clinical developments and future directions. ESMO Open. 2021;6:100003. doi:10.1016/j.esmoop.2020.100003 - DOI - PMC - PubMed
    1. Rudin CM, Brambilla E, Faivre‐Finn C, Sage J. Small‐Cell Lung Cancer. Nat Rev Dis Primers. 2021;7:3. doi:10.1038/s41572-020-00235-0 - DOI - PMC - PubMed
    1. Varghese AM, Zakowski MF, Yu HA, et al. Small‐cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9:892‐896. doi:10.1097/JTO.0000000000000142 - DOI - PMC - PubMed
    1. Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small‐cell lung cancer. Nat Rev Clin Oncol. 2020;17:300‐312. doi:10.1038/s41571-019-0316-z - DOI - PMC - PubMed

Publication types

MeSH terms

Substances